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Abstract
Background Weight loss and homeostatic disturbances of both energy and protein balances are characteristics of several
illnesses including cancer, heart failure, and chronic kidney disease (CKD). Different deﬁnitions have been used to describe this
deleterious process. The term protein-energy wasting (PEW) has been proposed for CKD patients by the International Society
of Renal Nutrition and Metabolism.
Methods We searched the publication in Medline from February 2008 to September 2018 using PEW or cachexia in their title.
Results Since its inception, the term PEW has been exceptionally successful, highlighted by 327 original publications refer-
enced in PubMed over 10 years. Using this classiﬁcation, several studies have conﬁrmed that PEW is among the strongest pre-
dictors of mortality in CKD patients [hazard ratio of 3.03; conﬁdence interval of 1.69–5.26 in 1068 haemodialysis patients and
1.40 (1.04–1.89) in 1487 non-dialysed patients across PEW stages 0 to 4]. Based on this classiﬁcation, prevalence of PEW is
28% to 54% among 16 434 adults undergoing maintenance dialysis. PEW prevalence increases when renal function declines,
that is, from<2% in CKD stages 1–2 to 11–54% in CKD stages 3–5. A more general deﬁnition of cachexia for all chronic diseases
proposed by the Society on Sarcopenia, Cachexia and Wasting Disorders was also published concurrently. In the CKD area, we
found 180 publications using ‘cachexia’ underlining that some confusion or overlap may exist. The deﬁnitions of PEW and ca-
chexia are somewhat similar, and the main difference is that a loss of body weight >5% is a mandatory criterion for cachexia
but supportive for PEW.
Conclusions The recent understanding of cachexia physiopathology during CKD progression suggests that PEW and cachexia
are closely related and that PEW corresponds the initial state of a continuous process that leads to cachexia, implicating the
same metabolic pathways as in other chronic diseases. Despite the success of the deﬁnition of PEW, using a more uniform
term such as ‘kidney disease cachexia’ could be more helpful to design future research through collaborative groups of re-
searchers with focus on cachexia.
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Protein-energy wasting/cachexia
prevalence
Nutritional deﬁciencies have long been recognized as an ad-
verse effect of chronic kidney disease (CKD) and are associ-
ated with reduced physical activity and poor survival.1–5
However, cachexia is poorly deﬁned and managed in these
patients, and a clearer deﬁnition of this condition is needed.
Indeed, the terms wasting, cachexia, malnutrition, protein-
energy malnutrition, and malnutrition–inﬂammation athero-
sclerosis (or cachexia) syndrome were used interchangeably,
which might have caused confusion. Hence, the exact criteria
used to deﬁne the prevalence of cachexia and protein-energy
wasting (PEW) in CKD were not consistent across studies,
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making it difﬁcult to aggregate data. Using a nutritional scor-
ing system such as the subjective global assessment or by
subjective global assessment or malnutrition–inﬂammation
score, the prevalence of cachexia/PEW was found to be 28–
80% of adults undergoing maintenance dialysis6–9 and as an
increasing prevalence when renal function declines. Indeed,
during stages 1–2 CKD, this prevalence is less than 2%9,10
and in stages 3–5 is estimated to be 11–46%.10–13 In the last
meta-analysis, including 16 434 patients on maintenance dial-
ysis, 25th–75th percentiles range in PEW prevalence was 28–
54%.14 During stages 3–5 in 1778 patients, PEW prevalence
was ranging from 11% to 54%.14
Deﬁnition of protein-energy wasting
and kidney cachexia
The term ‘wasting’ was proposed by the World Health Orga-
nization in 1983 and was deﬁned as an involuntary loss of
weight of more than 10% of patient’s previous value in ab-
sence of an opportunistic infection, cancer, or chronic diar-
rhea. Wasting or malnutrition were once believed to be
invariably caused by inadequate nutritional intake and should
be reserved for this situation only. If wasting is often present
in CKD in response to anorexia-induced insufﬁcient energy in-
take, it is not the only component of nutritional alterations. In
order to unify the description of the global systemic disorder
including the loss of homeostatic control of both energy and
protein balances, panels of experts participated in formal
consensus processes. A subsequent generic deﬁnition of ca-
chexia (for all types of cachexia) was published in 2008 by
the Society on Sarcopenia, Cachexia and Wasting Disorders.15
Cachexia was deﬁned as a complex metabolic syndrome asso-
ciated with underlying illness and characterized by a loss of
muscle, with or without loss of fat. At the same time, the In-
ternational Society of Renal Nutrition and Metabolism pro-
posed a speciﬁc classiﬁcation of uraemia-induced wasting
disorders in which cachexia was the most severe stage of
PEW.16 This classiﬁcation became successful and the message
fairly well reached the nephrology community. Ten years
later, a PubMed literature search (from inception to 12 Sep-
tember 2018) identiﬁed 327 CKD publications that used
PEW in their title (Figure 1). However, during the same pe-
riod, still in CKD, 180 publications used ‘cachexia’ underlining
that some confusion was still present.
What is the difference between
cachexia and protein-energy wasting in
chronic kidney disease?
As shown in Table 1, the diagnostic criteria for cachexia (pro-
posed by the Society on Sarcopenia, Cachexia and Wasting
Disorders)15 and for PEW (proposed by the ISRNM)16 are sim-
ilar, but not identical. However, there is no obvious distinc-
tion between PEW and cachexia from a pathophysiologic
standpoint, and limiting the term cachexia to extreme forms
of PEW is perhaps too restrictive. With our understanding
of the mechanisms involved in the PEW/cachexia, should
these deﬁnitions evolve and reconcile?
Body weight and body composition
The main criterion for cachexia (Table 1) is either a weight
loss >5% in the previous 12 months or a body mass index
(BMI) <20 kg/m2 and does not seem satisfactory in the
CKD context because low BMI is not always present at the
early stages of nutritional disorders. Indeed, due to a ten-
dency for elevated body weight in CKD, given that the aver-
age BMI of US dialysis patients is >25 kg/m2,17 waiting for
a low BMI to consider cachexia would certainly induce a late
diagnosis. In this regard, the use of BMI in the PEW deﬁnition
and cachexia has been challenged.18 It is the authors’ opinion
that a speciﬁc BMI cut-off level should not be considered any-
more in these classiﬁcations given racial and ethnic diversities
and because the information provided by BMI does not over-
come that brought by body weight. By contrast, weight loss is
an easy and more sensitive tool to monitor as the primary
clinical manifestation of cachexia. Indeed, body composition
Figure 1 PubMed search using ‘Protein energy wasting (PEW)’ or ‘cachexia’ in chronic kidney disease (CKD) keywords.
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is difﬁcult to measure with precision in a clinical setting. Body
weight loss remains a valid criterion; in a recent study includ-
ing almost 5000 patients, a signiﬁcant weight loss began rel-
atively early during the course of CKD and was associated
with a substantially higher risk for death after dialysis therapy
initiation.19 Overall, both classiﬁcations have identiﬁed a non-
voluntary weight loss as a phenotypical criterion based on a
robust literature: greater than 5% within the past 6 months
or >10% beyond 6 months as recently proposed by the
Global Leadership Initiative on Malnutrition.20 The presence
of a critical weight loss (>5% in 6 months) should probably
be considered as a major criterion to deﬁne cachexia/PEW.
By contrast, a more moderate weight loss (<5%) should be
considered as one criterion among others.
Muscle wasting (or sarcopenia) is obviously acknowledged
as an important feature in the pathophysiology of the ca-
chexia phenotype and predisposes to increased risk of co-
morbid complications.15,21,22 In both deﬁnitions, measures
of muscle mass by mid-arm muscle circumference area are
present. In contrast to PEW, the diagnostic criteria for ca-
chexia emphasize muscle functional measures (such as mus-
cle strength or fatigue). Indeed, muscle strength is an
independent predictor of renal outcomes in CKD patients
and can be helpful in diagnosing cachexia/PEW in this popu-
lation.23,24 In the PEW deﬁnition, creatinine appearance is
proposed to estimate muscle mass but its accuracy and re-
producibility are weak, and in our opinion, this criterion is
probably not used much nowadays.25 Mechanically, an in-
crease in muscle proteolysis by a common transcriptional
programme is always present despite the diverse nature of
cachexia, primarily through the ubiquitin-proteasome system
and the coordinated induction of atrophy-related genes
(atrogenes) by FOXO transcription factors.21,26,27
There is questioning about the role of fat in cachexia and
until now, fat loss is not considered as an important feature
of cachexia except in the PEW classiﬁcation. In epidemiologi-
cal studies, adipose tissue wasting has been associated with
an increased risk of death in different cachexia diseases.28–
30 The discovery about the ability of white adipose tissue to
be turned towards the brown adipose phenotype with ther-
mogenesis capacity, leading to increased energy expenditure
and lipid mobilization, underlines the importance of this
tissue in cachexia. Experimental data also suggest that this
phenomenon appears before skeletal muscle atrophy.31–33
The browning inductors could be similar in different cachexia
such as those induced by parathyroid hormone (PTH) in
CKD and PTH-related peptide (PTHrP) in cancer.33 In this
situation, PTH/PTHrP-induced fat-derived molecules, that is,
adipokines, free fatty acids, or other metabolites, mediate
the crosstalk between muscle and fat that contributes in a
major way to tissue catabolism. Despite this, there is cur-
rently no consensus about the optimal fat mass or fat loss
value suggesting the presence of PEW, and fat was not
retained in the last nutrition recommendation.20
Biological criteria
To assess nutritional disorders, biological criteria should be
able to identify and risk stratify patients with PEW/cachexia,
distinguishing the causes and consequences of PEW/cachexia
and the underlying diseases that lead to PEW/cachexia. How-
ever, some nutritional markers used in cachexia, such as
anaemia, are inﬂuenced by CKD and cannot be used. There
is also no consensus on the role and pertinence of inﬂamma-
tion in the criteria of PEW and cachexia. In the initial deﬁni-
tion of PEW, it was proposed that inﬂammation could be a
source of confusion by supposing that PEW was exclusively
because of inﬂammation.16 The central role of cytokines or
inﬂammation into the pathophysiology of cachexia is still an
outstanding question. Numerous experimental and clinical
data have highlighted that inﬂammation acts directly on tar-
get tissues as well as through alteration of central nervous
system (dysregulation of appetite), neuroendocrine targets
(such as the release of adrenal steroids), sickness behaviour
(such as anorexia and fatigue), and muscle catabolism.34
In cancer cachexia, the important role of inﬂammation is
now indisputably admitted. Numerous pro-inﬂammatory
cytokines are generated through tumour crosstalk with
associated stromal cells, and the immune system and inﬂam-
mation is the cornerstone of cancer cachexia.35 In CKD, in-
creased serum inﬂammatory cytokines predispose to the
pathogenesis of PEW.36–38 Accumulating data also suggest
that during CKD, speciﬁc accretion of uremic toxins may have
a direct effect on inﬂammation stimulation and cytokines
production.39 Therefore, inﬂammation contributes to PEW/
cachexia in several ways, both by direct and indirect mecha-
nisms of muscle proteolysis and by impinging upon and
magnifying other causes of PEW in a vicious circle. Therefore,
the rationale not to include inﬂammatory criteria in the
PEW criteria might be reconsidered.
Protein and energy intake
An unintentional reduction in dietary energy intake is a crite-
rion of both cachexia and PEW deﬁnitions. In the PEW–CKD
ﬁeld, an intake less than 25 kcal per kg body weight is
proposed, and for cachexia, it is 20 kcal per kg body weight.
It is recognized that there are pitfalls in identifying a decrease
in energy intake. In order to help energy intake management,
the gap between energy expenditure and energy intake can
be estimated from direct measures of resting energy expendi-
ture (indirect calorimetry) and indirect measures by records
of dietary intake.40 However, this is not routinely performed
and until now, there is no consensual value of a ‘low’ energy
intake. The other main difference is protein intake, which has
only been considered in the PEW deﬁnition. Although it is
generally accepted that the protein needs of cachectic pa-
tients are increased, the existing international guidelines on
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the optimal amounts of protein and amino acid intakes are
vague.41 This suggests that protein intake could be integrated
in the cachexia criteria and is not speciﬁc of the uremic con-
dition. For instance, a low protein diet is suggested for the
management of CKD with normal nutrition status.42
Conclusion
Assessment of protein and energy status is a broad and com-
plex topic, in particular in CKD. No consensus is available on
the deﬁnition of and methods for measuring skeletal muscle
depletion, reduced food intake, and the biological indicators
of altered metabolism. The aim of PEW nomenclature was
to unify terminology to describe a cachectic disorder that oc-
curs in many patients with CKD. The implementation of this
classiﬁcation was a great success, and contrary to the generic
cachexia deﬁnition proposed by Evans and co-workers,15 PEW
has been validated to predict mortality in several cohorts of
CKD patients.5,43 In addition, using a generic vs. a speciﬁc def-
inition in the kidney disease population has not been per-
formed so far. We do not know whether this may improve
diagnosis and management of adverse outcomes in these pa-
tients. However, differences between PEW16 and cachexia15
are very limited (Table 1) and without strong justiﬁcation. Ini-
tial triggers of cachexia may be different between chronic dis-
eases but the catabolic pathway and physiopathology are
very similar and induce a comparable phenotype. We would
like to suggest that PEW is cachexia and should be termed
‘kidney disease cachexia’ as a continuum with PEW ﬁrst
followed by cachexia. Substituting PEW by kidney disease
cachexia might be less confusing to describe a similar phe-
nomenon observed in other cachectic diseases as seen in can-
cer.22 Finally, cachexia deﬁnition should evolve to better
describe the reality and take into account fat loss and insufﬁ-
cient protein intake. Future research will undoubtedly dem-
onstrate and conﬁrm that criteria of cachexia are similar
and helpful in monitoring nutritional disorders in CKD.
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